Citations 4
Analysis of relationship between baseline body weight and efficacy/safety of yttrium 90 ( 90 Y) ibritumomab tiuxetan radioimmunotherapy in patients (pts) with non-Hodgkin's lymphoma (NHL)
Wiseman, Gregory A., Emmanouilides, Christos, Vo, Katie D. , Schilder, Russell J., Foster, Paul , Gordon, Leo I. , Witzig, Thomas E. , Molina, Aurelia Alañón
Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6700-6700
Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-Hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan
Emmanouilides, C., Czuczman, M. S., REVELL, S T, Wang, H. , Skikne, B. , Witzig, Thomas E. , Gordon, Leo I. , Foster, Paul , Molina, Aurelia Alañón
Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6696-6696
Long-term follow-up of a phase I/II trial of radioimmunotherapy (RIT) with yttrium 90 ( 90 Y) ibritumomab tiuxetan for CD20+ B-cell non-Hodgkin's lymphoma (NHL)
Emmanouilides, Christos, Raubitschek, Andrew, Darif, Mohamed, Schilder, Russell J., Wiseman, Gregory A., Gordon, Leo I. , Molina, Aurelia Alañón , White, C. A., Witzig, Thomas E.
Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 6574-6574
Yttrium 90 ibritumomab tiuxetan is safe and effective in older patients with relapsed or refractory NHL
Schilder, Russell J., Emmanouilides, C., Vo, Katie D. , Darif, Mohamed, Witzig, Thomas E. , Flinn, Ian W. , Gordon, Leo I. , Molina, Aurelia Alañón
Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6562-6562